Royal Caribbean (NYSE:RCL) stock finally caught a break. After sliding for most of the past month, Royal Caribbean shares soared more than 20% on Wednesday on elevated trading volume.Source: Laszlo Halasi / Shutterstock.com News of a potential novel coronavirus vaccine has the travel stocks surging again, and the cruise lines are right in the middle of the action. Before you get too excited, however, take a moment to consider Royal Caribbean's broader business outlook. While the vaccine news is a big plus, it's not enough to justify owning the stock as a long-term investment. Here's what you need to know. Vaccine Development Is AdvancingOn Tuesday, after the market closed, Moderna (NASDAQ:MRNA) announced favorable results for its Covid-19 vaccine candidate. The company told us that its vaccine produces a strong immune response in recipients. The company's trial was small, and there are some obstacles, such as the vaccine potentially requiring a booster shot to be effective.InvestorPlace – Stock Market News, Stock Advice & Trading TipsHowever, it appears to be a very positive development on the whole. This is causing a significant run-up in economic recovery/re-opening stocks.Cruise lines, like Royal Caribbean, have been the hardest-hit with the pandemic. The cruise companies had intended to start sailing again this summer, the second wave of the virus has caused that timeline to slip significantly. This vaccine news, if it holds up, should give cruise companies a real timeline toward getting back to business as usual.The vaccine news could also help cause a rotation from growth stocks to value names. Since March, investors have primarily focused on sectors such as software-as-a-service firms and healthcare companies whose businesses are growing or are at worst neutral as a result of the virus. * 15 Growth Stocks That Are Being Propped Up By Low RatesMeanwhile, stocks with direct exposure, such as banks, retailers and travel stocks have underperformed dramatically. The Nasdaq Composite Index has already hit new all-time highs, while most stocks with direct Covid-19 exposure remain way down from their pre-virus levels. Catalyst for Travel StocksWe could see a serious reversal of this trade in coming weeks. Up until now, we've had a ton of false starts around economic re-opening. While the skies would look clear one week, the next week we'd have states shutting things back down. California's recent move to shut restaurants and bars again was particularly demoralizing. The vaccine news could finally break this pattern and give vulnerable companies like cruise lines room for a sustained rebound.Improvement on the Covid-19 front should create a sizable rebound in travel companies, like RCL stock. However, don't assume things are actually going back to normal anytime soon. The virus has caused astounding economic damage.Even if we could get this vaccine widely-distributed tomorrow, it'd be too late to put the genie back in the bottle. Unemployment is way up and many businesses have shut down permanently. We aren't returning to 2019 levels of economic activity within a quarter or two, regardless. And Royal Caribbean, which sells entirely discretionary services to mostly middle class folks, isn't going to see business return to normal immediately. RCL Stock VerdictIf you're trading Royal Caribbean, Carnival (NYSE:CCL), or other travel stocks, this vaccine news is a gift. You should get one more big surge of trading interest that could cause a major lift for share prices in the short term.In coming weeks and months, however, people will figure out that even as the virus fades, Royal Caribbean remains a deeply-wounded company. It's not realistic to return to pre-Covid-19 share prices. The company lost too much money and weakened its balance sheet too much to return to pre-virus prosperity. Remember that it took on billions in additional debt this May at an 11% interest rate. This creates a huge ongoing interest burden that will be an anchor weighing the company down even if the industry returned to normal levels of activity.Ironically, on Wednesday, RCL stock soared far more than Moderna; Royal Caribbean was up 21% while Moderna jumped just 7%. Normally, you'd expect that the vaccine-maker would get the biggest bump on its own clinical trial results, but traders were desperate for anything positive in the travel names. That tells you something about sentiment.As such, if you own Royal Caribbean here, enjoy the rally, but keep one eye on the exits. This could be the last good opportunity to sell RCL stock before shares turn into a big value trap.Royal Caribbean's operating business is likely to remain depressed well into next year or even longer. RCL stock is vulnerable to downside if the vaccine development program suffers any setbacks. As such, Royal Caribbean is attractive only as a short-term trade.Ian Bezek has written more than 1,000 articles for InvestorPlace.com and Seeking Alpha. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. You can reach him on Twitter at @irbezek. At the time of this writing, he held no positions in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Vaccine News Is a Selling Opportunity for Royal Caribbean appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2OAFp5d

CrowdStrike Holdings, Inc. (Nasdaq: CRWD) has had an epic run this year and has more than tripled off its March novel coronavirus lows. That's not necessarily unusual for a tech stock these days, and particularly not for one based in the cloud. But what's next for CRWD stock, and does this cloud-based security darling still have further to run?Source: GuruFocus.com CRWD Stock: All About the CloudLong before Covid-19 turned the world upside down, the rise of cloud computing was one of the dominant themes of the past two decades. Amazon.com (NASDAQ: AMZN) essentially invented cloud computing as we know it today in 2006 via its AWS platform, and now it seems that virtually every major enterprise has moved at least part of their computing needs to cloud providers. The software-as-a-service model, in which users essentially rent web-based software as opposed to buying and installing software locally, is also part of this story.InvestorPlace – Stock Market News, Stock Advice & Trading TipsIt's cheaper and ultimately safer to keep data saved on a server than it is on a local hard drive, but the cloud model does create some security risks of its own. Each endpoint – every desktop, laptop, smart phone or other device used to log in – is a potential entry point for a malicious attack from a hacker. * 15 Growth Stocks That Are Being Propped Up By Low RatesThis is where CRWD stock comes in. CrowdStrike provides endpoint security, and it delivers it via the cloud. Its security software works behind the scenes, invisible to the end users, and the company claims its product reduces resource utilization by 25 times versus its competitors. In plain English, that means it won't bog down your device. Revenues Growing Like a WeedCRWD stock is still a baby, as its IPO was just a little over a year ago. But its revenues are growing at a blistering rate.Source: GuruFocusIn early 2018, quarterly revenues were less than $50 million. Today, they're closing in on $180 million and show no sign of slowing.That's the good news. The bad news is that the company isn't profitable. It hasn't had a single profitable quarter in its entire history as a company, or at least not on a GAAP basis.The losses are getting smaller – just $0.09 last quarter – and it's worth noting that the losses are mostly due to high marketing costs, which should presumably help to generate future growth. But as of today, the company has yet to actually make money.And then there is the share price. CRWD stock trades for about 40 times sales. 40 times earnings would be a little on the expensive side. This is 40 times sales. That's a really big bet on future growth that may or may not materialize. Should You Buy CRWD Stock?It pains me to say this because I'm a value investor at heart. But fundamentals really don't matter today, and neither do valuations. Today's market is driven by virtually infinite liquidity coming out of the Federal Reserve. All of the dollars the Fed is pumping into the financial system have to go somewhere, and many are finding their way into tech stocks.I don't know when the party ends. Frankly, I don't know how it's lasted this long in the face of a pandemic that doesn't seem to be getting any better. But with no obvious end to Fed stimulus, the bubble might continue to inflate for a while.Today, this market is favoring high-growth tech companies irrespective of earnings. CRWD stock certainly fits that bill, and I see no immediate catalyst to reverse its move.So, by all means, buy CRWD stock. Trade it. Ride it higher. But don't get married to it, and be prepared to sell when this growth regime shifts and value starts to matter again. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Why CrowdStrike Investors Should Be Prepared appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/3fJ6AXo

Can Canopy Growth (NYSE:CGC) break out over resistance? That's what investors want to know now that Canopy Growth stock, Aphria (NYSE:APHA), and others cannabis stocks are beginning to find some upside momentum. Source: Shutterstock If this group can get buyers to return, then we could see some powerful moves across the board. Cannabis and CoronavirusThe novel coronavirus caused a painful spill in the equity markets. However, many names have come roaring back to life. In some instances, like with the Nasdaq, these investments have gone on to hit new highs. InvestorPlace – Stock Market News, Stock Advice & Trading TipsCannabis stocks were starting to look better in the first quarter of 2020. That was after bottoming in Q4 and showing signs of moving higher. In any regard, cannabis stocks understandably sold off. Many of these names have inferior balance sheets — thankfully CGC stock isn't one of them — and have decelerating growth. In this case, names like Tilray (NASDAQ:TLRY) and Aurora Cannabis (NYSE:ACB) have struggled immensely. * 15 Growth Stocks That Are Being Propped Up By Low Rates Click to EnlargeThat's even as some research suggests that cannabis sales held up fine during the coronavirus outbreak. In fact, some reports show that lockdown orders helped to accelerate cannabis sales. But that's not the narrative. Instead, shares declined in the coronavirus selloff as investors didn't want to own stocks with shaky financials. Further, any cannabis legislation that was sitting on a governor or government official's desk was pushed aside for Covid-19. Eventually these legislations will be addressed, but a delay is not a positive catalyst in the short-term. Canopy Growth Stock Has Staying PowerOn the plus side, Canopy Growth isn't one of those stocks with shoddy financials. The company boasts $2.56 billion in current assets and $6.8 billion in total assets. Those sums dominate current and total liabilities, which come in at just $420.5 million and $1.75 billion, respectively. Admittedly, Canopy Growth is not profitable or free cash flow positive yet. So continuing operations will further erode its balance sheet over time. But that is true for virtually all of the industry at this point. In the case of CGC stock, its assets are large enough to buoy its business in the meantime. It helps that it has Constellation Brands (NYSE:STZ) as its largest holder. At some point, the company could become the majority shareholder and that has helped to keep Canopy's bank accounts adequately supplied. The company recently exercised its warrants to bring its total stake in Canopy up to 38.6%. Bottom Line on Canopy Growth Click to EnlargeSource: Chart courtesy of TradingViewI like Canopy Growth, even though the industry has had trouble gaining some traction. This is the leading stock in this group, and when the sector catches some momentum, so too with CGC stock. Canopy is making moves into the U.S., first sinking into the CBD market to drive U.S. sales. It will also be in position for if (and more likely when) cannabis becomes legal at the federal level. The company has also shuffled up its management team, which should help turn the page to a more optimistic future. Obviously the coronavirus will come with its own headaches, but by and large, cannabis is being more widely accepted and that is a positive for the group over the long-term. On the charts, CGC stock is starting to rotate over the $18.30 area. It's also putting in a series of higher lows and maintaining over the 20-day and 50-day moving averages. If shares can clear this area and the 200-day moving average, the May highs near $22 could be in play. What if shares don't gain enough momentum to break out? In that case, technical traders will want to keep an eye on the $16.50 level. That's where uptrend support (blue line) comes into play. However, if this level is lost, it also means that the 20-day and 50-day moving averages failed in supporting the stock. That could put the July and June lows in play, at $15.57 and $15.32, respectively.Matthew McCall left Wall Street to actually help investors — by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. Click here to see what Matt has up his sleeve now. As of this writing, Matt did not hold a position in any of the aforementioned securities.  More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Momentum in Canopy Growth Stock Could Send Shares to $22 appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/3jhNRnP

Under the traditional or commonplace definition, cyclical stocks are investments that are largely impacted by macroeconomic events. In a bull market, for instance, you'll see Wall Street top dogs transition into cyclical sectors to advantage growth opportunities. Of course, with the incredibly disruptive novel coronavirus, all bets are off the table.Or are they? To be sure, conservative investors will want to give their portfolio a healthy dose of secular names, or assets that perform reliably well irrespective of market conditions. And some of these investments, such as food-related securities, are acting very much like cyclical stocks due to their newfound relevance and momentum.However, for those that can stomach a little risk, genuine cyclical stocks have an opportunity for potentially massive upside. Unlike other recessionary periods, the new normal was arguably not caused by an economic vulnerability. Prior to the pandemic, one of our fiscal headwinds was the U.S.-China trade war. Still, both sides were making headway until disaster struck.InvestorPlace – Stock Market News, Stock Advice & Trading TipsThus, it's not unreasonable to assume that some cyclical stocks will bounce back once the coronavirus fades away or until we have a vaccine. Once we get back to normal – as in, a real normal – these companies could enjoy a so-called V-shaped recovery: * Microsoft (NASDAQ:MSFT) * FireEye (NASDAQ:FEYE) * Blink Charging (NASDAQ:BLNK) * Honda (NYSE:HMC) * Albemarle Corporation (NYSE:ALB) * Newmont Corporation (NYSE:NEM) * Smith & Wesson Brands (NASDAQ:SWBI) * Sportsman's Warehouse (NASDAQ:SPWH) * Canopy Growth (NYSE:CGC) * 15 Growth Stocks That Are Being Propped Up By Low Rates Finally, keep in mind that the Covid-19 outbreak has not dampened our innovative or resourceful spirit. In some ways, the coronavirus has shifted our priorities. And these nine cyclical stocks to buy stand to benefit from this unprecedented transition. Microsoft (MSFT)Source: NYCStock / Shutterstock.com Shortly after the pandemic disrupted most Americans' ability to make a living, the rise of a new set of cyclical stocks – the work-from-home sector – captured everyone's attention. Logically, you can benefit from this phenomenon through trending names like Slack Technologies (NYSE:WORK), Dropbox (NASDAQ:DBX), and of course Zoom Video Communications (NASDAQ:ZM). But I'm going to start off with a classic: Microsoft.While the other names I mentioned provide specialized solutions, in this crisis, it doesn't hurt to have a jack-of-all-trades. But don't say that Microsoft isn't a master of none because that's far from the truth. As a freelancer myself, I have always found the company's products to be lifesavers. Yes, other competing platforms exist, but they don't have the same cachet. Therefore, I love the long-term potential of MSFT stock.And it's not just my words. Microsoft saw its earnings jump in the first quarter of this year thanks to robust cloud-computing demand during the pandemic. With the coronavirus again rearing its ugly head – aided perhaps by stupid people in this country – MSFT stock might enjoy its own resurgence. FireEye (FEYE) Click to EnlargeSource: Michael Vi / Shutterstock.com While employees are probably loving the transition to remote work, management may soon have a different take. No, I'm not talking about suspicions that your supervisor may have about you actually working from home. Rather, the shift to telecommuting opens a new battleground for cybercriminals. Because of this rather fortuitous event for cybersecurity firms, this may finally be the moment for FireEye.Don't get me wrong: if you're looking for cyclical stocks in this space, you're better off with stable competitors like Palo Alto Networks (NYSE:PANW) or Check Point Software Technologies (NASDAQ:CHKP). However, FEYE stock is rather attractive because of its low price and favorable fundamentals. Frankly, there's never been a more crucial time for enterprises to protect their digital ecosystem. Thus, FireEye may benefit from a rising tide. * 10 Work-From-Home Stocks That Are Beating the Pandemic Also, Morgan Stanley raised its price target for FEYE stock to $13 from $12. Although I don't recommend blindly following analysts' forecasts, they may have a point here. Plus, this is the best chance that FEYE has ever had for upside. Blink Charging (BLNK)Source: David Tonelson/Shutterstock.com Earlier this year, Blink Charging shares were barely above penny stock status. Admittedly, it got very scary following the initial attack from the coronavirus.Since the March doldrums, though, BLNK stock has blossomed into one of the most compelling cyclical stocks to buy. What's more remarkable is that in the past five years, shares were all over the map. Back then, electric vehicles represented only a small portion of automobile sales. And to be clear, that hasn't changed much. What has changed is the attitude.You see, the oil price falling below zero wasn't just an unprecedented, though thankfully temporary calamity. It also was emblematic of a decided consumer shift toward cleaner fuel vehicles. Therefore, the much-discussed hype about a massive transition to electric now has credibility.But what has practically prevented mainstreaming of EVs is infrastructure. After all, not every driver has access to a garage. That's where Blink Charging comes into play with its network of charging stations. Thanks to the aforementioned consumer shift, BLNK stock should be a long-term winner. Honda (HMC)Source: Jonathan Weiss / Shutterstock.com If you're looking to invest in the EV space, you should primarily focus on Tesla (NASDAQ:TSLA). Even if you don't like the nominal price tag of TSLA, you could always opt for fractional ownership via platforms like Robinhood. That's probably why gravity seemingly has no effect on Tesla.Still, there's something to be said about going for the obvious pick. If you want to enjoy the advantages of cyclical stocks in the EV market but want something with perhaps higher profitability potential, you might want to check out Honda.As EVs become mainstream, I believe that consumers will expect more from their automotive brands. Though Tesla has a tremendous lead in the space, they don't stack up too well in terms of reliability. Also, many Tesla owners in the past have been frustrated with the company's slow repair times. These misfires could provide an underappreciated opportunity for HMC stock as Honda prepares to go EV only from 2025.As everyone knows, Honda has built a longstanding reputation for reliability. It's not that much of a stretch to assume it will apply the same principle to EVs. Also, Honda's extensive dealership networks could provide far superior service for customers. * 8 Presidential Election Stocks to Buy in Case Trump Wins Again Of course, this is a riskier contrarian play. But if you prefer unconventional thinking, HMC stock could be your ticket to success. Albemarle Corporation (ALB)Source: IgorGolovniov/Shutterstock.com Out of all the high-probability cyclical stocks available, those levered to the EV market could witness the biggest gains. From true energy independence to environmental concerns, electric power hits the right notes for the emerging generation. However, picking individual EV players is fraught with risk. To mitigate the dangers to your portfolio, you may want to consider Albemarle Corporation.An industry leader in lithium and lithium derivatives, Albemarle essentially acts as an umbrella investment. At a certain point, you'd expect auto rivals to challenge Tesla's throne. Though Tesla enjoys brand dominance, it can't possibly sell to every American driver. For instance, the company is leaving open the economy car segment, which should see intense competition. And that just translates to higher demand for lithium, boosting ALB stock.Theoretically, EVs are easier to make, which is another reason why automakers are rushing into the arena. Just the presence of mass (and viable) competition could shake things up at Tesla. But for ALB stock, more competition will bring in more consistent revenues. Newmont Corporation (NEM)Source: Piotr Swat/Shutterstock To be perfectly honest, cyclical stocks related to the gold industry have relied on an old but dangerous adage: "this time, it's different." Unfortunately, every time someone uttered this phrase following gold's record-breaking move last decade, enthusiasm quickly met with disappointment. Nevertheless, I'm bullish on Newmont Corporation.First, this time, it really is different. Though we've suffered pandemics in our past, we've never encountered one that forced state governments to shut their economies. Typically, gold rises on fear and uncertainty, and there's plenty of that going around. Thus, with higher demand for the underlying commodity, NEM stock is finally enjoying a credible fundamental tailwind.Second, the resurgent coronavirus is almost screaming the case for gold-related investments. Obviously, another round of state shutdowns will cause much calamity. With federal relief funds to support the unemployed about to expire soon, NEM stock could jump on the fear trade. * The 7 Best Stocks to Invest in Right Now But the biggest catalyst could be the Federal Reserve. Given that no playbook exists for responding to this crisis, the central bank will probably adopt an inflationary policy. This could be the spark that sends gold prices to absolutely ridiculous levels. Smith & Wesson Brands (SWBI)Source: Supakorn Pe / Shutterstock.com Not all rises in cyclical stocks are due to uplifting reasons. Case in point is the unbelievable growth in Smith & Wesson Brands. Ironically, SWBI stock didn't do all that well under the Trump administration. First, the fear of Democrats taking away people's firearms just didn't exist. Second, crime went down during his first term, although many question the President's role in this trend.But now, the narrative has completely changed. The coronavirus exposed Trump as an effective leader only in good times. When the chips are down, he appears vulnerable. Unfortunately for him, this disaster struck on a pivotal election year.Analyzing the dynamics of the political race, I still believe Trump has a shot of winning. However, that's an unpopular opinion and the rise of SWBI stock reflects this.Also bolstering the case for Smith & Wesson is that violent crime is now surging in major U.S. cities. With law enforcement departments throughout the U.S. beleaguered due to nationwide calls for justice, individual citizens are left with few options other than to take matters into their own hands. Sportsman's Warehouse (SPWH)Source: OpturaDesign/Shutterstock.com With a second wave of infections hitting us like a freight train, we are almost surely headed toward an ugly recession. Yes, the White House has boasted about record-breaking jobs gains in May and June. However, most of that came from low-paying service sector occupations that partially returned when states began reopening.Now, that's off the table. Logically, that will translate to a truly ugly jobs report for either July or August. And that doesn't bode well for cyclical stocks geared toward the retail market. However, investors should make an exception for Sportsman's Warehouse.Because of the word "sports" in the company name, you might think that this is an athletic apparel retailer. You're not too far off. I call Sportsman's Warehouse Nike (NYSE:NKE) for coalminers.Basically, it sells guns – lots and lots of guns. As I mentioned with Smith & Wesson, this is a very popular sector; hence, the meteoric rise in SPWH stock.Additionally, I'm not sure when the enthusiasm will end. While cries for defunding the police may sound good for some political groups, I'm positive that it's scaring the heck out of most people. Of course, due to cancel culture, they're not going to admit that. * 9 Ugly Natural Gas Stocks to Keep on Your Watchlist Instead, they're buying guns, which is why you should look into buying SPWH stock. Canopy Growth (CGC)Source: Shutterstock When Canada became the first G7 member state to legalize recreational marijuana, many folks – including yours truly – thought that this would usher in a transformative paradigm shift. From my perspective, we were talking about turning a previously illegal market into a legal and therefore taxable one. So, I was excited about Canopy Growth and CGC stock. Eventually, though, that excitement turned into disappointment.In hindsight, Canopy like so many of its rivals focused almost exclusively on growth. Unfortunately, the legal cannabis market in Canada was not prepared to handle the rollout. Much of the setbacks came from the government, specifically cannabis license application backlogs. Also, not enough dispensaries existed in high-demand provinces, causing supply-demand bottlenecks.Still, that's not to excuse the business leaders in this market. They made poor decisions, which ultimately hurt investments like CGC stock.However, the coronavirus could give controversial cyclical stocks like CGC another lease on life. Specifically, the new normal has been tough on mental health. Though research is still being conducted in this area, cannabis and non-psychoactive cannabidiol (CBD) may offer organic relief.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he is long gold. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 9 Cyclical Stocks Whose Time Is Coming Around appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2CtTO0z

Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Equity Income Fund posted a return of 18.29% for the quarter, underperforming its benchmark, the S&P 500 Index which returned 20.55% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for investors […]

from Yahoo Finance https://ift.tt/2WMnmO3

Intuitive Surgical soared to a record high a couple of days after breaking out. The maker of robotic surgical systems likely benefiting from coronavirus vaccine hopes. A vaccine would let surgeries go back to normal. The only problem with ISRG – besides being extended now – is that earnings are due Tuesday night.

from Yahoo Finance https://ift.tt/2ZGUWqo

Stocks go up, stocks go down, you can't explain that…Or maybe you can, if the stock happen to be a biotech that just flunked a clinical trial. Which leads us nicely to Celsion Corporation (CLSN). Or not so nicely if you happen to be an investor.Shares cratered by a dispiriting 68% this week after the company announced that the independent Data Monitoring Committee (DMC) recommended it prematurely bring to an end its Phase 3 OPTIMA study evaluating ThermoDox in patients with primary liver cancer.Based on an interim safety and efficacy analysis, the DMC concluded the study was unlikely to achieve the primary endpoint after exceeding a futility threshold value.With Celsion still assessing the data, management have outlined 3 possible paths forward: “1) continuation of the study through final analysis, 2) discontinuation of the study for futility, and lastly 3) assessment of the study following some additional events (n=8–10).”For Oppenheimer analyst Hartag Singh, the well-designed study’s results were obviously “disappointing.”Although the analyst points out that Celsion management has indicated “a potential preference for the (inexpensive) third option,” it is doubtful the outcome will be any different.With ThermoDox likely to be discarded, attention will now turn to GEN-1, the biotech’s treatment for ovarian cancer – a notoriously hard to treat disease. GEN-1 has shown promise in the first part of a phase 1/2 trial and has been given the go ahead to continue with the second portion, which will be initiated in August. While it is still early days, Singh is piqued by the reaction to the initial data.The 5-star analyst said, “While we expect to see more on GEN-1, particularly as the Phase 2 program initiates in August, work may lay ahead on the manufacturing front, and we await a broader data set. Nonetheless, initial results have been intriguing: a 2x higher R0 resection rate in newly-diagnosed Stage III/IV ovarian cancer (over historical) generating significant physician enthusiasm for the approach.”However, for now, along with removing ThermoDox from his Celsion model, Singh drops his rating from Outperform (i.e. Buy) to Perform (i.e. Hold) and takes his price target off the table. (To watch Singh’s track record, click here)Overall, two other analysts recently reviewed Celsion’s prospects, one saying Buy, while the other suggesting Hold. (See Celsion stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * $1000 Is the Number to Watch for Shopify Stock, Says 5-Star Analyst * Q2 Semiconductor Preview: What to Expect * Oppenheimer: These 2 "Strong Buy" Stocks Are Poised to Surge by Over 80% * Dynavax Teams Up With Mt Sinai On Universal Flu Vaccine

from Yahoo Finance https://ift.tt/2CmbmeQ

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

from Yahoo Finance https://ift.tt/2WtnzVY